Home › Funds › DV EQUITIES, LLC › DNTH
DV EQUITIES, LLC position in DNTH
DIANTHUS THERAPEUTICS INC · Health Care
DV EQUITIES, LLC reported holding 21,051 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.36% of its reported portfolio and ranking #37 among its reported holdings. DV EQUITIES, LLC has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How DV EQUITIES, LLC's DNTH position evolved
DV EQUITIES, LLC first disclosed a stake in DNTH in Q2 2026 at 21,051 shares (US$2.1M). Across 2 filings, DV EQUITIES, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 21,051 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 21.05K | $2.05M | New |
| Q3 2026 | 21.05K | $1.85M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$223.4M), Avidity Partners Management LP (US$167.3M), Octagon Capital Advisors LP (US$148.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $223.40M · Q3 2026
- Avidity Partners Management LP 1.90M sh · $167.26M · Q3 2026
- Octagon Capital Advisors LP 1.69M sh · $148.51M · Q3 2026
- TCG Crossover Management, LLC 1.68M sh · $147.63M · Q3 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $114.60M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 914.00K sh · $80.48M · Q3 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $75.03M · Q3 2026
- Venrock Adviser, LLC 822.02K sh · $72.38M · Q3 2026
- BRAIDWELL LP 518.40K sh · $45.64M · Q3 2026
- Logos Global Management LP 500.00K sh · $44.02M · Q3 2026
- Cormorant Asset Management, LP 500.00K sh · $44.02M · Q3 2026
- Spruce Street Capital LP 354.82K sh · $31.24M · Q3 2026
More on DV EQUITIES, LLC
FAQ
How long has DV EQUITIES, LLC held DNTH?
DV EQUITIES, LLC has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is DV EQUITIES, LLC's current position in DNTH?
As of Q3 2026, DV EQUITIES, LLC holds 21.05K shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $1.85M, representing 0.36% of its reported portfolio and ranking #37.
Has DV EQUITIES, LLC been buying or selling DNTH?
In the latest 13F filing (Q3 2026), DV EQUITIES, LLC held unchanged its position in DNTH.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.